96 related articles for article (PubMed ID: 23580151)
1. Imatinib induces body mass changes in women with chronic myeloid leukemia.
Breccia M; Salaroli A; Serrao A; Zacheo I; Alimena G
Ann Hematol; 2013 Nov; 92(11):1581-2. PubMed ID: 23580151
[No Abstract] [Full Text] [Related]
2. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
3. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Mabed M; Elhefni AM; Damnhouri G
Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
[No Abstract] [Full Text] [Related]
4. Imatinib-associated melanosis of the palate.
Roeker LE; Wolanskyj AP
Am J Hematol; 2014 May; 89(5):564. PubMed ID: 24030927
[No Abstract] [Full Text] [Related]
5. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
[No Abstract] [Full Text] [Related]
6. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
7. Pseudoporphyria induced by imatinib mesylate.
Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
[No Abstract] [Full Text] [Related]
8. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
Barton JC; Jones SC; Lamberth WC; Reymann MT; Scott VC
Am J Hematol; 2002 Oct; 71(2):139-40. PubMed ID: 12353320
[No Abstract] [Full Text] [Related]
9. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
Millot F; Guilhot J; Baruchel A; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Nicolas Sirvent ; Yacouben K; Chastagner P; Gandemer V; Reguerre Y; Couillault G; Khalifeh T; Rialland F
Eur J Cancer; 2014 Dec; 50(18):3206-11. PubMed ID: 25459396
[TBL] [Abstract][Full Text] [Related]
10. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
[TBL] [Abstract][Full Text] [Related]
11. Vocal fold hemorrhage in a CML patient after Glivec treatment.
Shim HS; Woo SH
Acta Oncol; 2013 May; 52(4):866-8. PubMed ID: 23153030
[No Abstract] [Full Text] [Related]
12. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
13. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
14. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.
Berman E; Girotra M; Cheng C; Chanel S; Maki R; Shelat M; Strauss HW; Fleisher M; Heller G; Farooki A
Leuk Res; 2013 Jul; 37(7):790-4. PubMed ID: 23473999
[TBL] [Abstract][Full Text] [Related]
15. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
[No Abstract] [Full Text] [Related]
16. Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.
Cervetti G; Carulli G; Galimberti S; Azzarà A; Cannizzo E; Buda G; Orciuolo E; Petrini M
Leuk Res; 2008 Jan; 32(1):191-2. PubMed ID: 17397920
[No Abstract] [Full Text] [Related]
17. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
18. Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia.
Cervetti G; Carulli G; Galimberti S; Azzarà A; Buda G; Orciuolo E; Pelosini M; Petrini M
Leuk Res; 2008 Jan; 32(1):194-5. PubMed ID: 17459473
[No Abstract] [Full Text] [Related]
19. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.
Ohyashiki K; Kuriyama Y; Nakajima A; Tauchi T; Ito Y; Miyazawa H; Kimura Y; Serizawa H; Ebihara Y
Leukemia; 2002 Oct; 16(10):2160-1. PubMed ID: 12357373
[No Abstract] [Full Text] [Related]
20. [Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review].
Wang YD; Cui GH; You Y; Li M; Xia J; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):743-6. PubMed ID: 23336229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
